# Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

> **NCT05171816** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 110 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

- **DRUG:** olaparib
- **DRUG:** abiraterone acetate

## Key facts

- **NCT ID:** NCT05171816
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-24
- **Primary completion:** 2024-01-22
- **Final completion:** 2026-04-28
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05171816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05171816, "Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05171816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*